Abstract Library

#1159 Mixed Adenoneuroendocrine Carcinomas (MANECs) of the Gastrointestinal Tract. ARGENTUM Group

Introduction: Mixed adenoneuroendocrine carcinomas of the gastrointestinal tract are rare neoplasms. In the 2000 WHO classification of endocrine tumors, such neoplasms were defined as mixed exocrine-endocrine tumors when each component represents at least 30% of the lesion. In the most recent WHO classification, such neoplasms are called “mixed adenoneuroendocrine carcinomas” (MANECs). They are a challenge for the diagnostic and treatment.

Conference: 12th Annual ENETSConcerence (2015)

Presenting Author:

Authors: Cabanne A, Bestani C, Pesce V, O'Connor J, Kujaruk M,

Keywords: MANEC, NETs,

#1157 Cardiac Evaluation as Part of the Initial Extension Studies in Neuroendocrine Tumors. Experience in a Multidisciplinary Team. ARGENTUM GROUP

Introduction: Carcinoid heart disease (CHD) is a complication of metastatic neuroendocrine tumors and is screened for using echocardiography. Published case series showed that when cardiological evaluation is done at least 50% of the patients have CHD, and 33% had surgical indication.

Conference: 12th Annual ENETSConcerence (2015)

Presenting Author: santos_chacon@ciudad.com.ar D

Authors: Santos D, O'Connor J, Pesce V, Bestani C, Belli S,

Keywords: Cardiac heart disease, neuroendocrine tumors,

#1154 Selective Internal Radiation Therapy (SIRT) Radioembolisation with 90 Yttrium in Patients with Unresectable Liver Neuroendocrine Metastases in a Specialized Center. An Initial Report

Introduction: Most patients with neuroendocrine tumors present liver metastases at some point of the clinical course. Liver directed treatment, such as 90 Yttrium is a method of treatment used in patients with non-resectable liver lesions, which is effective in the control of symptoms and tumor growth.

Conference: 12th Annual ENETSConcerence (2015)

Presenting Author: García Mónaco R

Authors: García Mónaco R, Peralta O, O'Connor J, Pesce V, Bestani C,

Keywords: 90Yttrium, radioembolization, neuroendocrine tumors ,

#1147 Correlation of Serum Plasma Chromogranin A with Survival and Disease Features in Patients with Gastroenteropancreatic Neuroendocrine Tumors. First Results in a Large Database in Argentina. ARGENTUM GROUP.

Introduction: The plasma chromogranin A (CgA) is the best general biomarker in gastroenteropancreatic neuroendocrine tumors (GEP-NETs). CrA levels are elevated in a variety of GEP-NETs and are used to aid in diagnosis, prognosis, and monitoring of treatment effects in this population.

Conference: 12th Annual ENETSConcerence (2015)

Presenting Author: Belli S

Authors: Belli S, O'Connor J, Oneto A, Pesce V, Bestani C,

Keywords: neuroendocrine tumor, chromogranin A, prognostic factor ,

#715 Neuroendocrine Tumors of the Rectum: Experience in Argentina

Introduction: Neuroendocrine tumors (NETs) of the rectum have been increasing in incidence. They are approximately 18% the all NETs and 27% of all gastrointestinal NETs. Rectal NETs are usually small and are often found incidentally during endoscopy. Patients (pts) with local disease have a favorable prognosis of a 5-year survival rate of 88-91%. Optimal treatment of NETs of the rectum has been widely debated.

Conference: 10th Annual ENETSConcerence (2013)

Presenting Author:

Authors: Bestani C, Pesce V, O'Connor J, Cabanne A, Mendez G,

Keywords: rectal NETs,